SIME Diagnostics is a global Medtech company headquartered in London, dedicated to shaping a future without acute respiratory disease. Founded in 2014 by Professor Agnar Hoskuldsson and Professor Henrik Verder, SIME's goal is to revolutionize medicine by predicting respiratory disease within minutes at the point-of-care. Their patented platform consists of a compact cloud-connected device and reagent-free disposable, designed for use in intensive care units.

This innovative technology enables the prediction of acute respiratory diseases within 15 minutes, using routinely collected samples. The first product to market is a rapid test for neonatal lung maturity (respiratory distress syndrome). In addition to their predictive diagnostics, SIME's Clinical AI Platform generates millions of unique data points.

These data points are analyzed by proprietary AI to drive rapid product development and deliver novel disease insights. SIME's revolutionary tool empowers critical care clinicians by providing quick and informed patient triaging decisions in the ICU and NICU. Their CE Marked Clinical AI Platform is now available for investigational use, promising to be one of the most promising prognostic tools in acute respiratory care.

SIME Diagnostics is on a mission to reduce mortality and morbidity in the ICU and NICU and create a world where respiratory disease is no longer a leading cause of health issues in these settings